When Does 2 Plus 2 Equal 5? A Review of Antimicrobial Synergy Testing

被引:313
作者
Doern, Christopher D. [1 ]
机构
[1] Virginia Commonwealth Univ, Med Ctr, Richmond, VA 23284 USA
关键词
CYSTIC-FIBROSIS; PSEUDOMONAS-AERUGINOSA; TIME-KILL; ANTIBIOTIC SUSCEPTIBILITY; BURKHOLDERIA-CEPACIA; ENTEROCOCCUS-FAECIUM; CHECKERBOARD METHODS; COMBINATION; RESISTANT; VANCOMYCIN;
D O I
10.1128/JCM.01121-14
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In this age of emerging antibiotic resistance, limited therapeutic options exist for treating multidrug-resistant organisms. Combination therapy is commonly employed to manage these infections despite little laboratory guidance as to the efficacy of this approach. Synergy testing methods have been used to assess the interaction of antibiotic combinations in vitro. This review will discuss the four primary methods used to assess synergy, as well as the data that exist for testing of cystic fibrosis. In the final analysis, this review concludes that there is not enough evidence to endorse synergy testing for routine clinical use.
引用
收藏
页码:4124 / 4128
页数:5
相关论文
共 27 条
[1]   Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial [J].
Aaron, SD ;
Vandemheen, KL ;
Ferris, W ;
Fergusson, D ;
Tullis, E ;
Haase, D ;
Berthiaume, Y ;
Brown, N ;
Wilcox, P ;
Yazghatlian, V ;
Bye, P ;
Bell, S ;
Chan, F ;
Rose, B ;
Jeanneret, A ;
Stephenson, A ;
Noseworthy, M ;
Freitag, A ;
Paterson, N ;
Doucette, S ;
Harbour, C ;
Ruel, M ;
MacDonald, N .
LANCET, 2005, 366 (9484) :463-471
[2]   Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia [J].
Aaron, SD ;
Ferris, W ;
Henry, DA ;
Speert, DP ;
MacDonald, NE .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 161 (04) :1206-1212
[3]   Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms [J].
Aaron, Shawn D. .
PAEDIATRIC RESPIRATORY REVIEWS, 2007, 8 (03) :256-261
[4]  
[Anonymous], 1999, Methods for determining bactericidal activity of antimicrobial agents
[5]  
approved guideline M26-A, V19
[6]   Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients [J].
Balke, B ;
Hogardt, M ;
Schmoldt, S ;
Hoy, L ;
Weissbrodt, H ;
Häussler, S .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2006, 25 (01) :25-30
[7]   Evaluation of antibiotic synergy against Acinetobacter baumannii:: a comparison with Etest, time-kill, and checkerboard methods [J].
Bonapace, CR ;
White, RL ;
Friedrich, LV ;
Bosso, JA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 38 (01) :43-50
[8]   Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa [J].
Cappelletty, DM ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :677-683
[9]  
Clinical and Laboratory Standards Institute (CLSI), 2014, M100S24 CLSI S
[10]   Cystic Fibrosis Pulmonary Guidelines Treatment of Pulmonary Exacerbations [J].
Flume, Patrick A. ;
Mogayzel, Peter J., Jr. ;
Robinson, Karen A. ;
Goss, Christopher H. ;
Rosenblatt, Randall L. ;
Kuhn, Robert J. ;
Marshall, Bruce C. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 180 (09) :802-808